|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regorafenibmonotherapy for previously treated metastatic colorectalcancer (CORRECT): an international, multicentre,ran-domised, placebo- controlled, phase 3 trial 显示文摘 | Grothey A Cutsem EV Sobrero A | 2013 | Lancet2013，381，9863： | 1 |
| 2 | Oral Capecitabine vs intravenous 5 -fluorouracil and leueovorin: integrated efficacy data and novel analyses from two large, randomised phase III trials显示文摘 | Van Cutsem EV Hoff PM Harper P | 2004 | Br J Cancer2004，90，6： | 1 |
| 3 | Efficacy results from theToGA trial:A phaseⅢstudy of trastuzumab added to standardchemotherapy(CT)in first-line human epidermal growth factor re-ceptor 2(HER2)-positive advanced gastric cancer(GC)显示文摘 | Cutsem EV Kang Y Chunget H | 2009 | JClin Oncol2009，27，18： | 1 |
| 4 | AVAGAST:A randomized,double-blind,placebo-controlled,phaseⅢstudy of firstlinecapecitabine and cisplatin plus bevacizumab or placebo in patientswith advanced gastric cancer(AGC)显示文摘 | Kang Y Ohtsu A Cutsem EV | 2010 | J Clin Oncol2010，28，18： | 1 |
| 5 | Phase III study of docetaxel and cisplatin plus fluorouracil compared with 'cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group显示文摘 | Cutsem EV Moiseyenko VM Tjulandin S | 2007 | Clin Oncol2007，25，17： | 1 |
| 6 | AVANT: Results from a randomized, three-arm multinational phase III study to in- vestigate bevacizumab with either XELOX or FOLFOXg versus FOLFOX4 alone as adjuvant treatment for colon cancer 显示文摘 | de Gramont A Cutsem EV Tabernero J | 2011 | J Clin Oncol2011，29，4： | 1 |
| 7 | Updated effica- cy of the MEK inhibitor trametinib(T),BRAF inhibitor dabrafenib (D),and anti-EGFR antibody panitumumab (P)in patients(pts)with BRAF V600E mutated(BRAFm) metastatic colorectal cancer (mCRC) 显示文摘 | Atreya CE Cutsem EV Bendell JC | 2015 | J Clin Oncol2015，33，15： | 1 |
| 8 | Efficacy results from the ToGA trial:a phase Ⅲ study of trastuzumab added to standard chemotherapy(CT)in first-line human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer(GC)显示文摘 | Cutsem EV Kang Y Chung H | 2009 | J Clin Oncol(Meeting Abstracts)2009，27，18： | 1 |
| 9 | Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:A report of the V325 Study Group显示文摘 | Cutsem EV Moiseyenko VM Tjulandin S | 2006 | J Clin Oncol2006，24，： | 1 |
| 10 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2 positive advanced gastric or gastroesophageal junction cancer (TOGA):a phase 3, open- lable, randomized controlled trial 显示文摘 | Bang YJ Cutsem EV Feyereislova A | 2010 | Lancet2010，376，9742： | 1 |
| 11 | Docetaxel(D),cisplatin,5-fluorouracil compare to cisplatin(C) and 5-fluorouracil(F) for chemotherapy negative patients with metastatic or locally recurrent,unresectable gastric carcinoma(MGC):Interrim results of arandomized phase1 E trial(V325)显示文摘 | Ajani JA Cutsem EV Roth AD | 2003 | Proc Soc Clin Oncol2003，22，6： | 1 |
| 12 | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer显示文摘 | Cutsem EV Kohne CH Hitre E | 2009 | N Engl J Med2009，360，14： | 1 |
| 13 | Phase III study of docetaxel and eisplatin plus fluorottraeil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric Cancer:a repo of the V325 study group显示文摘 | Cutsem EV Moiseyenko VM Tjulandin S | 2006 | JCO2006，24，： | 1 |
| 14 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin:integrated efficacy data and novel analyses from two large,randomized,phase Ⅲ trials显示文摘 | Cutsem EV Hoff PM Harper P | 2004 | Br J Cancer2004，90，6： | 1 |
| 15 | Efficacy resuhs from the ToGA trial: A phase m study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)- positive advanced gastric cancer (GC) 显示文摘 | Cutsem EV Kang Y Chung H | 2009 | J Clin Oneol (Meeting Abstracts)2009，27，18： | 1 |
| 16 | Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase Ⅱ study显示文摘 | Findlay M Osterwalder B | 2000 | J Clin Oncol2000，18，： | 1 |
| 17 | Randomized phase Ⅲ study of irinotecan and 5-FU/FA with orwithout cetuximab in the first-line treat ment of patients with metastatic colorectal cancer(mCRC):the CRYSTAL trial显示文摘 | Cutsem EV Nowacki M Lang I | 2007 | J Clin Oncol2007，25，18： | 1 |
| 18 | Oral capecitabine compared with intravenous fluorouracil plus leucovorin in pa- tients with metastatic colorectal cancer: Results of a large phase III study 显示文摘 | Cutsem EV Twelves C Cassidy J | 2001 | J Clin Oncol2001，19，21： | 1 |
| 19 | Novel cytotoxic regimens in gastric cancer显示文摘 | Cutsem EV | 2006 | EJC2006，4，： | 1 |
| 20 | Phase HI study of doc- etaxel and cisplatin plus fluomuracil compared with cisplatin and fluo- rouracil as firstline therapy for advanced gastric cancer:a report of the V325 study group 显示文摘 | Cutsem EV Moiseyenko VM Tjulandin S | 2006 | JCO2006，24，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员